No Data
Why Investors Shouldn't Be Surprised By Guilin Sanjin Pharmaceutical Co., Ltd.'s (SZSE:002275) Low P/E
Guilin Sanjin Pharmaceutical (SZSE:002275) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years
Guilin Sanjin Pharmaceutical (002275.SZ) distributed 2.5 yuan per 10 shares in the first three quarters, with a record date of November 25th.
Guilin Sanjin Pharmaceutical (002275.SZ) announced that the company will implement the distribution of equity for the first three quarters of 2024, every 1...
Guilin Sanjin: Report for the third quarter of 2024
Guilin Sanjin Pharmaceutical (002275.SZ): The net income for the first three quarters was 0.384 billion yuan, a 3.28% year-on-year decrease.
Gelonghui October 29th | Guilin Sanjin Pharmaceutical (002275.SZ) announced the third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 1.575 billion yuan, a year-on-year decrease of 3.49%; net income attributable to shareholders of the listed company was 0.384 billion yuan, a year-on-year decrease of 3.28%; net income after deducting non-recurring gains and losses was 0.347 billion yuan, a year-on-year decrease of 7.78%; basic earnings per share was 0.65 yuan per share.
Guilin Sanjin Pharmaceutical (002275.SZ) released its performance for the first three quarters, with a net income of 0.384 billion yuan, a 3.28% year-on-year decrease.
guilin sanjin pharmaceutical (002275.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...
Guilin Sanjin Pharmaceutical Co., Ltd. (SZSE:002275) Looks Inexpensive But Perhaps Not Attractive Enough
